Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Capricor Therapeutics, Inc. (NASDAQ: CAPR).

Full DD Report for CAPR

You must become a subscriber to view this report.

Recent News from (NASDAQ: CAPR)

Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q1 2018 Results - Earnings Call Transcript
Capricor Therapeutics, Inc. (CAPR) Q1 2018 Earnings Conference Call May 10, 2018 04:30 PM ET Executives AJ Bergmann - Chief Financial Officer Linda Marbán - President and Chief Executive Officer Analysts Joseph Pantginis - H.C. Wainwright Presentation Operator ...
Source: SeekingAlpha
Date: May, 10 2018 19:53
Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
HOPE-2 Clinical Trial is Currently Enrolling Patients Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 10, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological...
Source: GlobeNewswire
Date: May, 10 2018 16:00
Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10
LOS ANGELES, May 04, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its f...
Source: GlobeNewswire
Date: May, 04 2018 08:00
Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal
LOS ANGELES, May 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that  Linda Marbán, Ph.D., Capricor president and CEO, will provide a presentation on exosomes at the plenary session of the International Society for Cellular Therapy (ISCT) 2018 M...
Source: GlobeNewswire
Date: May, 03 2018 07:00
Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay
Karyopharm (KPTI) slumped 17% in the pre-market yesterday, ahead of data from a mid stage study of selinexor in treatment-resistant multiple myeloma. A couple of years ago, this same drug was pitted against Darzalex in the same indication and showed similar efficacy. An FDA filing was planned ...
Source: SeekingAlpha
Date: May, 02 2018 08:00
Solid Biosciences moving closer to removal of clinical hold on early-stage study of DMD candidate SGT-001; shares up 6%
Thinly traded Solid Biosciences ( SLDB +5.5% ) is up, albeit on turnover of only 85K shares, on its announcement that it has received a letter from FDA concerning the full clinical hold on its Phase 1/2 study of gene therapy SGT-001 in patients with Duchenne muscular dystrophy. The agenc...
Source: SeekingAlpha
Date: April, 30 2018 13:43
Capricor launches mid-stage study of DMD candidate CAP-1002; shares up 2%
Capricor Therapeutics ( CAPR +1.5% ) initiates a Phase 2 clinical trial, HOPE-2 , assessing CAP-1002 in boys and young men with Duchenne muscular dystrophy (DMD). More news on: Capricor Therapeutics, Inc., Sarepta Therapeutics, Inc., Catabasis Pharmaceuticals, Healthcare stocks news, ...
Source: SeekingAlpha
Date: April, 30 2018 13:23
Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy
LOS ANGELES, April 30, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics , Inc. (NASDAQ:CAPR) today announced it has initiated the HOPE-2 clinical trial at UC Davis Medical Center. The trial will test the safety and efficacy of Capricor’s novel cellular therapy, CAP-1002, in boys and...
Source: GlobeNewswire
Date: April, 30 2018 07:00
Wired News - Capricor's New Pre-Clinical Study Establishes that Repeated Doses of CAP-1002 Lead to Enhanced Exercise Capacity in a Disease Model of Duchenne Muscular Dystrophy
Stock Monitor: Kala Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 23, 2018 / has just released a free research report on Capricor Therapeutics, Inc. (NASDAQ: CAPR ) ("Capricor"). If you want access to this report all you need to do is sign up now...
Date: April, 23 2018 07:40
Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
LOS ANGELES, April 19, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that  researchers found that repeat dosing of the company’s proprietary cellular therapy yields an increase in exercise performance in a disease model of Duchenne muscular dystr...
Source: GlobeNewswire
Date: April, 19 2018 07:00


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CAPR.

About Capricor Therapeutics, Inc. (NASDAQ: CAPR)

Logo for Capricor Therapeutics, Inc. (NASDAQ: CAPR)

Los Angeles based Capricor Therapeutics, Inc. CAPR is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and large molecule products for the treatment of diseases. The Company has six drug candidates in stages of development which includes CAP , CAP , CSps, Exosomes, Cenderitide and CU NP. Capricor s lead product candidate, an allogeneic cardiosphere derived cell CDC product, CAP , aims to attenuate and potentially improve damage to the heart caused by a heart attack and is currently under evaluation in the Phase I/II ALLSTAR clinical trial of patients days to year after a heart attack. Ongoing research at Capricor focuses on in depth product characterization, expanded use of current products, development of next generation products, and identification of new technologies. The company was founded in and is headquartered in Beverly Hills, CA.


Contact Information



Current Management

  • Dr. Linda Marban / CEO
    • Dr. Marb n is currently serving as our Chief Executive Officer. Cofounder of Capricor, Inc., a privatelyheld company and our whollyowned subsidiary, Dr. Marb n has been with Capricor, Inc. since and became its Chief Executive Officer in . She combines her background in research with her business experience to lead Capricor, Inc. and create a path to commercialization for its novel stemcell cardiac therapies. Dr. Marb n was the lead negotiator in procuring the license agreements that are the foundation of Capricor, Inc. s intellectual property portfolio. Under her direction as Chief Executive Officer, Capricor, Inc. secured approximately . million in nondilutive grants and a loan award which funds Capricor, Inc. s R amp D programs and clinical trials involving its CAP product. Dr. Marb n s deep knowledge of the cardiac space, in particular, allows her to provide unique direction for the Company s development and growth. From to , Dr. Marb n was with Excigen, Inc., a biotechnology startup company, where she was responsible for business development, operations, preclinical research, and supervising the development of gene therapy products in a joint development agreement with Genzyme Corp. While at Excigen, she also negotiated a joint development and sublicense agreement with Medtronic Corp. utilizing Excigen s technology and supervised the building of a lab in which the work was to be performed. Dr. Marb n began her career in academic science, first at the Cleveland Clinic Foundation working on the biophysical properties of cardiac muscle. That work continued when she moved to a postdoctoral fellowship at Johns Hopkins University, or JHU.
  • Karen Krasney / EVP
    • Ms. Krasney is currently serving as our Executive Vice President, Secretary and General Counsel. Ms. Krasney s career spans over years serving as General Counsel for numerous corporations and private companies engaged in a wide variety of industries. Her extensive background and vast experience has been focused on domestic and international corporate and business law, as well as litigation. Ms. Krasney has been involved in the medical technology arena since the mid s, representing several medical technology companies developing products for the treatment of cardiovascular disease. Commencing in , Ms. Krasney served as legal counsel of Biosensors International Group Ltd., a multinational medical device company that develops, manufactures and sells medical devices for cardiology applications. In , she accepted the position of General Counsel and Executive Vice President of Biosensors and served in that capacity until . During her tenure at Biosensors, among other things, Ms. Krasney headed the legal team that facilitated the company s successful initial public offering in Singapore and was responsible for negotiating and documenting all agreements for the company worldwide, including licensing agreements with major medical device companies and agreements required for the company s international clinical trials. Ms. Krasney has been providing legal services to Capricor since and in joined Capricor as its Executive Vice President and General Counsel. Ms. Krasney also serves as a director on the Board of Cardiovascular Research Foundation, a nonprofit research and education entity. Ms. Krasney received her Bachelor of Arts degree from the University of California, Los Angeles and her Juris Doctorate from the University of Southern California.
  • AJ Bergmann / VP, Fin.
    • Mr. Bergmann currently serves as our Vice President of Finance. Mr. Bergmann previously worked at the business management firm, Gettleson, Witzer and O Connor, in Beverly Hills, California beginning in , where he focused on accounting and finance for several production studios generating motion picture releases and worldwide revenue exceeding billion. The firm s clients included foundations, trusts, and independent actors, writers, producers and directors across the entertainment industry. While at the firm, he focused on budgeting, tax forecasting and asset management. Mr. Bergmann joined Capricor in and served as the Director of Finance until November . He was recently made Vice President of Finance of Capricor. He also serves as Capricor s corporate treasurer. Mr. Bergmann was instrumental in facilitating the company s Series A . million Preferred Stock offering and helped structure the company s successful . million budget proposal to the California Institute for Regenerative Medicine for the company s Phase II clinical trial. Mr. Bergmann is responsible for all aspects of the Company s finance, accounting and human resource functions. Mr. Bergmann graduated from Providence College with a BS in Management, and a minor in Finance. He has an MBA from the University of Southern California s Marshall School of Business. He is actively involved in various venture capital and entrepreneurial associations throughout the Los Angeles area.
  • Rachel Smith / VP, R amp D
    • Dr. Smith is currently serving as our Vice President of Research and Development. Dr. Smith joined Capricor in and is a coinventor of the CardiosphereTM technology that forms the core of Capricor s product portfolio. She also published the seminal proofofconcept paper demonstrating the clinical utility of the Cardiospherederived stem cells in models of heart disease. Her research expertise encompasses the areas of stem cell biology, cardiac physiology, electrophysiology, as well as cell and tissue engineering. In , Dr. Smith was appointed Vice President of Research and Development of Capricor and is responsible for developing the company s clinical trial protocols and managing its regulatory and research partner relationships. Dr. Smith obtained her Ph.D. in Biomedical Engineering from Johns Hopkins University under the advisement of Dr. Eduardo Marb n and with the support of a Whitaker Foundation Graduate Fellowship and a National Science Foundation Graduate Fellowship. She received her undergraduate degree in Biomedical Engineering, Magna Cum Laude, from Tulane University.
  • Andrew Hamer / Vice President
    • Dr. Hamer is currently serving as our Vice President of Medical Affairs. He completed internal medicine and cardiology training at Green Lane Hospital in Auckland, New Zealand, having completed his degree in medicine from Otago University. Dr. Hamer also completed a Senior Cardiology Fellowship at the Deaconess Hospital and at Harvard Medical School in Boston. He served as Chairman of the New Zealand branch of the Cardiac Society of Australia and New Zealand from to . In , Dr. Hamer also cochaired the Cardiac Surgery Services Development Working Group CSSDG . In , Dr. Hamer was selected by the Minister of Health to lead the development of the National Cardiac Surgery Clinical Network to oversee the implementation of the CSSDG recommendations, leading to substantial improvements in cardiac surgery delivery in New Zealand. In , Dr. Hamer was asked to lead the expansion of the network to incorporate all of the cardiac services, forming the New Zealand Cardiac Clinical Network. In this role he led the implementation of national strategies to improve the equity and access to cardiac services and the establishment of national registries for acute coronary syndrome, percutaneous coronary intervention and cardiac surgery to enable continuous quality improvement from a local to national level. Dr. Hamer joined Capricor in November as the Vice President of Medical Affairs. Throughout this time, Dr. Hamer has been a cardiologist and internal medicine specialist at Nelson Hospital, where he has been a principal investigator for over multicenter clinical trials in acute coronary syndrome, cholesterol, hypertension, heart failure, diabetes and atrial fibrillation management

Current Share Structure

  • Market Cap: $36,302,927 - 05/14/2018
  • Authorized: 50,000,000 - 11/12/2014
  • Issue and Outstanding: 27,712,158 - 03/20/2018


Recent Filings from (NASDAQ: CAPR)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 04 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 19 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 05 2018



Daily Technical Chart for (NASDAQ: CAPR)

Daily Technical Chart for (NASDAQ: CAPR)

Stay tuned for daily updates and more on (NASDAQ: CAPR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CAPR)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CAPR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CAPR and does not buy, sell, or trade any shares of CAPR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: